Peripheral Neuropathy Treatment Market, by Indication (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and others), by Treatment (Pharmacological Therapies(Pain Relievers, Anti-seizure Medicati

Peripheral Neuropathy Treatment Market, by Indication (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and others), by Treatment (Pharmacological Therapies(Pain Relievers, Anti-seizure Medications, Antidepressants) and Non-pharmacological Therapies (Transcutaneous Electrical Nerve Stimulation, Plasma Exchange, and Others), by End User (Hospital, Ambulatory Centers, and Others), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Peripheral neuropathy is a disorder of the peripheral nerves. These nerves send messages between the central nervous system, the brain and the spinal cord, and the rest of the body. Peripheral neuropathy can result from traumatic injuries, infections, metabolic problems, inherited causes, and exposure to toxins. One of the most common causes is diabetes. Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. Individual with peripheral neuropathy generally describe the pain as stabbing, burning or tingling. In many cases, symptoms improve, especially if caused by a treatable condition. Medications such as Lyrica, Cymbalta, etc can reduce the pain of peripheral neuropathy.

Market Dynamics

Key players operating in the global peripheral neuropathy treatment market are focusing on adoption growth strategies such as product launch, and approval which are expected to drive the market growth during the forecast period. For instance, in July 2019, Alembic Pharmaceuticals Limited, an Indian pharmaceutical company, announced that it received the approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pregabalin Capsules that is used for peripheral neuropathic pain. Moreover, various government agencies focusing on investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy which is expected to drive the market growth over forecast period. For instance, in November 2018, the U.S. National Cancer Institute awarded/invested US$ 2.3 Mn in Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs.

Key features of the study:

  • This report provides an in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global peripheral neuropathy treatment market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy’s Laboratories Ltd, Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., and NeuroBo Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.
Detailed Segmentation:
  • Global Peripheral Neuropathy Treatment Market, By Indication :
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • Global Peripheral Neuropathy Treatment Market, By Treatment :
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • Global Peripheral Neuropathy Treatment Market, By End User :
  • Hospital
  • Ambulatory Centers
  • Others
  • Global Peripheral Neuropathy Treatment Market, By Region:
  • North America
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Others
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Abbott Laboratories*
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Dr. Reddy’s Laboratories Ltd
  • Pfizer, Inc.
  • Cipla Inc.
  • Lupin Limited
  • Averitas Pharma, Inc.
  • NeuroBo Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Indication
Market Snapshot, By Treatment
Market Snapshot, By End User
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Opportunity
Impact Analysis
Pipeline Analysis
Reimbursement Scenario
Epidemiology
PEST Analysis
Regulatory Scenario
New Product Approvals/Launches
Acquisition and Collaboration
Market Trends
4. Global Peripheral Neuropathy Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
COVID-19 Impact on Overall Healthcare Sector
COVID-19 Epidemiology
COVID-19 Impact on Clinical Trials and Drug Development
5. Global Peripheral Neuropathy Treatment Market, By Indication, 2017-2030, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Diabetic Peripheral Neuropathy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Chemotherapy-induced Peripheral Neuropathy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Idiopathic Peripheral Neuropathy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
6. Global Peripheral Neuropathy Treatment Market, By Treatment, 2017-2030, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Pharmacological Therapies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Pain Relievers
Anti-seizure Medications
Anti-depressants
Non-pharmacological Therapies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Others
7. Global Peripheral Neuropathy Treatment Market, By End User, 2017-2030, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Hospital
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Ambulatory Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
8. Global Peripheral Neuropathy Treatment Market, By Region, 2017-2030, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2022 and 2030 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2028
Regional Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
U.K.
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Heat Map Analysis
Abbott Laboratories
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Teva Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Johnson & Johnson
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Reddy’s Laboratories Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Pfizer, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Cipla Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Lupin Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Averitas Pharma, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
NeuroBo Pharmaceuticals, Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views
10. Section
Research Methodology
About us
*Browse 62 market data tables and 32 figures on "Global Peripheral Neuropathy Treatment Market” - forecast to 2030

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings